Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what bothers me about this Springmeds promotion of Icosapent Ethyl is I tried to find the Branded Vascepa cost and it appears to me that this company doesn't offer the branded? So they are only offering the generic and promoting it as the only choice Generic. Maybe I am wrong but that doesn't seem right to me.
Good bye
This is very exciting data for me. I am a Vascular surgery nurse practitioner. When I saw the results of the Reduce It study I knew that PAD results would also be found as clinically significant. Arterial disease is not exclusive to the heart but also throughout the body. This is only the beginning. I am keeping my fingers crossed for the results on Monday as I believe they also will be clinically significant.
I agree with you. Amarin much to my dismay has taken a huge hit due to generics and the Judge Du decision. I think going overseas is a big deal but time and money consuming. I think they did the right thing releasing sales reps in the US and I have not seen commercials in a while. This strategy hits them with lower prescriptions but also lowers generics prescriptions. These strategies will decrease overall cost. In the meantime overseas sales will hopefully pick up quickly and time will tell if the judicial systems rights a huge wrong(my opinion).
Being an inpatient NP makes it difficult because I am not part of the primary practice where prevention and management takes place. I am part of the after affects working on already block arteries. One thing I have noticed is a few patients have been started on Vascepa.
Good morning, Thank you for the questions. I work in a level one Trauma center. We have 7 cardiac surgeons, 13 interventional cardiologists and 10 vascular surgeons. They are all big cardiac and vascular practices. I am with the Vascular surgeons but most of our patients are the same patients. The reason for that is plaque within the blood vessels is not selective to the heart nor to the peripheral vessels. When plaque is in one vessel it is either the start of a cascade or found in multiple vessels. Better placement to stents through any of these methods does help with better stent placement however it also is what happens within the vessels over time that matters. So far even with our best efforts plaque build up occurs. Hence, everyone that leaves the hospital from our practices are being mandated by the hospital to leave on aspirin and a statin unless the patient refuses. It is like plumbing in your house. You use a snake to remove a clog containing hair build up etc. But 1, 2, 3 years later you develop the same build up. I truly believe Vascepa is a better answer than aspirin and yes even statin. We have used these medicines for years and patients keep coming back.
I wish I did. Vascepa is really in its infancy. That would definitely be a great study to prove the benefit of Vascepa over aspirin and/or plavix. Talking about increasing prescriptions....Vascepa replacing aspirin and/or plavix. I see first hand patients coming back time and time again for vascular surgery and procedures on plavix and aspirin
That is a great question. The vascular surgeons I work with have varying times of being on Plavix post stent placement, up to 3 months post however if over time multiple stents placed may be on Plavix lifelong. Aspirin is always life long after CAD or PVD diagnosis however I am not sure studies support that these days. We have used more than 2 agents sometimes throwing in Eliquis(for afib patients) in the mix in some cases especially for short term immediately after stent placement. My personal opinion is that Vascepa should take the place of both Aspirin and Plavix and I believe the outcomes would be better due to prevention and regression being the key to prescribing Vascepa.
Being a cardiovascular nurse practitioner I wanted to bring up a couple of points from a previous discussion regarding stents placed for CAD and I believe also should be included stents placed for PVD. Stents are not forever. Cardiologist and Vascular surgeons do their best to keep stents open with statins, Plavix and aspirin however once you have CAD or PVD you have it. These diseases are intertwined as they deal with diseased blood vessels. That is why to me Vascepa is so important in the prevention/treatment/regression of these diseases. Stents are a temporary fix as prevention is everything and Vascepa does that
It is not an angiogram it is a cardiac cath with Stent placement which automatically gets you not only a statin and aspirin but plavix as well. Prevention is everything in cardiac disease. When you have cardiac disease you also have a high likelihood of peripheral vascular disease as well.
Being a cardiac nurse practitioner, I don't agree. Everyday we start patients on a statin and if they don't tolerate one we start a different one. It is a primary prevention as Vascepa should be in my opinion. In my area we are just starting to see a few patients come through on Vascepa. I am hoping it becomes more wide spread for all cardiac patients as preventative
What is the newest patent please?
Meaning you are spending money on something that is not the real deal, not proven to do anything and you can't even be confident on what you are actually taking
I guess I don't understand. How is this OTC EPA getting the pure EPA if generic DRL is taking Amarin to court because there is limited supply due to Amarin and their contracts for supply? Also, Hikma is having a hard time with supply so how is the over the counter company's getting pure EPA?
Adds ready-to-administer injectable product to companies' existing partnership. Vascepa is oral
Thank you!
I have been looking for script #'s from last week. Can someone please post them if you have them? Thank you!
I agree with you. In Amarin's case it would get rid of the BS but also give them more cash on US sales to carry them into EU, China and the ROW. Some how this debacle needs to be rectified. So frustrating!
I think Amarin should go over the counter with Vascepa. No insurance companies, no physicians, no pharmacies, no lawyers, no judges, no regulations, no patents, no FDA. Just Amazon and GNC and Amarin and many healthy people
This is Yahoo at its best printing and no retraction
Shares of Amarin (NASDAQ: AMRN) were tumbling 5.5% lower as of 10:40 a.m. EDT on Wednesday after falling as much as 7.2% earlier in the session. The decline came after Goldman Sachs downgraded the stock from a neutral rating to sell and slashed its price target from $5 per share to $1.
https://finance.yahoo.com › quote › AMRN › news
This is Bezinga printing the truth
Amarin shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered its price target from $6 to $5 per share.
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
May 12, 2021 7:24am
Vote No
Strong balance sheet: Ended first quarter 2021 with $538.7 million in total cash and investments and no debt.
Adding to the list: Norwegian Medicines Agency informed Amarin of its marketing authorization for VAZKEPA in Norway.
I am confused this Press release is from 4/17/2020?
Every published article, every conference, every commercial, every educational pamphlet, every physician discussion, every research study outcome brings the benefits of Vascepa out to the public. Share price does not matter at this point. In the years to come most of the general population around the world will be on Vascepa and that is the goal.
reddit
r/Amarin · Posted by u/Business-Following-2 2h ago
Icosapent ethyl-risk of stroke reduced by an additional 36%
[https://newsroom.heart.org/news/adding-triglyceride-lowering-omega-3-based-medication-to-statins-may-lower-stroke-risk]
UHC, perhaps in response to AMRN legal wrangling's will not cover for TG>500 but will cover ≥150 for CARDIOVASCULAR RISK REDUCTION (PA). Big NO to generics here as they are not labeled for this indication??
the 3 most widely prescribed brand-name combination drugs were Benicar HCT (olmesartan and hydrochlorothiazide), Azor (amlodipine and olmesartan), and Nuedexta (dextromethorphan and quinidine).
Percocet=oxycodone and acetaminophen
Please send a copy of this letter to Amarin. This would be great as evidence of infringement
Does vitamin E interfere with any medications?
Consumption of high-dose vitamin E supplements ( ≥ 300 mg/d), however, may lead to interactions with the drugs aspirin, warfarin, tamoxifen and cyclosporine A that may alter their activities
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets
Dec. 24, 2020 at 11:38 a.m. ET on GuruFocus.com
INVESTOR RELATIONS / AMARIN TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS AND HOST CONFERENCE CALL ON FEBRUARY 25, 2021
Back
PDF Version
Feb 17, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2020 financial results and provide an operational update on Thursday, February 25, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
Conference Call and Webcast Information:
Amarin will host a conference call February 25, 2021, at 7:30 a.m. ET to discuss this information.
You should send a copy of that letter to Amarin.
Yes it is like the US Adcom
3.1.13. icosapent ethyl - EMEA/H/C/005398
is indicated to reduce cardiovascular risk as an adjunct to statin therapy.
Scope: Opinion
Action: For adoption
List of Outstanding Issues adopted on 10.12.2020, 17.09.2020. List of Questions adopted
on 26.03.2020.
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
How long does EMA approval take?
Following a CHMP opinion the European Commission takes usually its decision, a legally binding authorization, after 67 days.
If CHMP approves in January than that takes us into beginning of April potential depending on when in January?